{"article_id": "A_q4_2020.txt", "article": ["core revenue growth excludes the impact of currency and the acquisitions and divestitures completed within the past 12 months .", "we posted revenues of $ 1.48 billion during the quarter .", "revenues are up 8 % on a reported basis and up 6 % core .", "operating margins are a healthy 24.9 % .", "eps of $ 0.98 is up 10 % year - over - year .", "overall , covid - 19 tailwinds contributed just over 2 points of core growth .", "our life sciences and applied markets group generated $ 671 million in revenue , up 8 % on a reported basis and up 4 % core .", "the agilent crosslab group came in with revenues at $ 518 million .", "this is up a reported 9 % and up 7 % core .", "for the diagnostics and genomics group , revenues were $ 294 million , up 9 % reported and up 7 % core .", "growth was broad based , with nasd oligo manufacturing revenues up roughly 40 % .", "we generated $ 5.34 billion in revenue , up 3 % on a reported basis and up nearly 1 % core .", "in q1 , we delivered 2 % core growth , as you saw the first impact of covid - 19 in our business in china .", "with 6 % core growth , 8 % reported in q4 , we 're seeing business and economies start to recover .", "in a very tough capex market , our lsag instrument business declined only 2 % for the year and returned to growth in the final quarter .", "full - year earnings per share grew 5 % during fiscal 2020 to $ 3.28 .", "the full - year operating margin of 23.5 % is up 20 basis points over fiscal 2019 .", "in total , the cell analysis business generated more than $ 300 million in revenue for us during the year , with double - digit growth in q4 and continued strong growth prospects .", "similar to last year , i was talking about ramping up our new frederick site facility , a $ 185 million capital investment .", "we also recently announced additional $ 150 million investment to our future manufacturing capacity .", "for the quarter , revenue was $ 1.48 billion , reflecting core revenue growth of 5.6 % .", "reported growth was stronger at 8.5 % .", "currency contributed 1.7 % , while m&a added 1.2 points to growth .", "from an end - market perspective , pharma , our largest market , showed strength across all regions and delivered 12 % growth in the quarter .", "the food market also experienced double - digit growth during the quarter , posting a 16 % increase in revenue .", "and as mike noted earlier , our chemical and energy market exceeded our expectations , growing 3 % after two quarters of double - digit declines .", "diagnostics and clinical revenue grew 1 % during q4 , led by recovery in the u.s. and europe .", "for the quarter , china finished with 13 % growth and ended the full year up 7 % .", "the americas delivered a strong performance during the quarter , growing 5 % with results driven by large pharma , food , and chemical and energy .", "and in europe , we grew 2 % as we saw lab activity improved sequentially , benefiting from our on - demand service business in acg , as well as from a rebound in pathology and genomics as elective procedures and screening started to resume .", "fourth quarter gross margin was 55 % .", "this was down 150 basis points year - over - year , primarily by a shift in revenue mix and an unfavorable impact of fx on margin .", "in terms of operating margin , our fourth quarter margin was 24.9 % .", "this is down 20 basis points from q4 of last year , as we made some incremental growth - focused investments in marketing and r&d , which we expect to benefit us in the coming year .", "the quarter also capped off in full - year operating margin of 23.5 % , an increase of 20 basis points over fiscal 2019 .", "now wrapping up the income statement , our non-gaap earnings per share for the quarter came in at $ 0.98 , up 10 % versus last year .", "our full - year earnings per share of $ 3.28 increased 5 % .", "in q4 , we had operating cash flow of $ 377 million , up more than $ 60 million over last year .", "and in q4 , we continued our balanced capital approach , repurchasing 2.48 million shares for $ 250 million .", "for the year , we repurchased just over 5.2 million shares for $ 469 million and ended the fiscal year in a strong financial position with $ 1.4 billion in cash and just under $ 2.4 billion in debt .", "for the full year , we 're expecting revenue to range between $ 5.6 billion and $ 5.7 billion , representing reported growth of 5 % to 7 % and core growth of 4 % to 6 % .", "we expect operating margin expansion of 50 basis points to 70 basis points for the year , as we absorb the build out costs of the second line in our frederick , colorado nasd site .", "and then helping you build out your models , we 're planning for a tax rate of 14.75 % , which is based on current tax policies and 309 million of fully diluted shares outstanding , and this includes only anti-dilutive share buybacks .", "all this translates to a fiscal year 2021 non-gaap earnings per share expected to be between $ 3.57 and $ 3.67 per share , resulting in double - digit growth at the midpoint .", "finally , we expect operating cash flow of approximately $ 1 billion to $ 1.05 billion and an increase in capital expenditures to $ 200 million , driven by our nasd expansion .", "we have also announced raising our dividend by 8 % , continuing an important streak of dividend increases , providing another source of value to our shareholders .", "for q1 , we 're expecting revenue to range from $ 1.42 billion to $ 1.43 billion , representing reported growth of 4.5 % to 5.5 % and core growth of 3.5 % to 4.5 % .", "and first quarter 2021 non-gaap earnings are expected to be in the range of $ 0.85 to $ 0.88 per share ."], "summary_gold": "q4 non -gaap earnings per share $ 0.98 .<q>q4 revenue $ 1.48 billion versus refinitiv ibes estimate of $ 1.4 billion .<q>sees q1 revenue $ 1.42 billion to $ 1.43 billion .<q>sees fy 2021 revenue $ 5.6 billion to $ 5.7 billion .<q>sees q1 non -gaap earnings per share $ 0.85 to $ 0.88 .<q>sees q1 revenue up 4.5 to 5.5 percent .", "summary_pred": "full - year earnings per share grew 5 % during fiscal 2020 to $ 3.28 .<q>overall , covid - 19 tailwinds contributed just over 2 points of core growth .<q>reported growth was stronger at 8.5 % .<q>fourth quarter gross margin was 55 % .<q>this was down 150 basis points year - over - year , primarily by a shift in revenue mix and an unfavorable impact of fx on margin .<q>this is down 20 basis points from q4 of last year , as we made some incremental growth - focused investments in marketing and r&d , which we expect to benefit us in the coming year .<q>with 6 % core growth , 8 % reported in q4 , we 're seeing business and economies start to recover .<q>for the quarter , revenue was $ 1.48 billion , reflecting core revenue growth of 5.6 % .<q>we also recently announced additional $ 150 million investment to our future manufacturing capacity .<q>in terms of operating margin , our fourth quarter margin was 24.9 % .<q>and in europe , we grew 2 % as we saw lab activity improved sequentially , benefiting from our on - demand service business in acg , as well as from a rebound in pathology and genomics as elective procedures and screening started to resume .<q>currency contributed 1.7 % , while m&a added 1.2 points to growth .<q>our life sciences and applied markets group generated $ 671 million in revenue , up 8 % on a reported basis and up 4 % core .<q>for the year , we repurchased just over 5.2 million shares for $ 469 million and ended the fiscal year in a strong financial position with $ 1.4 billion in cash and just under $ 2.4 billion in debt .<q>finally , we expect operating cash flow of approximately $ 1 billion to $ 1.05 billion and an increase in capital expenditures to $ 200 million , driven by our nasd expansion .<q>the agilent crosslab group came in with revenues at $ 518 million .", "len_article": 48, "len_summary_gold": 6, "len_summary_pred": 16, "len_sent_scores": 48}